Call Us: +91-9915015108
Piperacillin/tazobactam is a combination antibiotic containing the extended-spectrum penicillin antibiotic piperacillin and the β-lactamase inhibitor tazobactam. The combination has activity against many Gram-positive and Gram-negative pathogens and
Piperacillin and Tazobactam for injection is an injectable antibacterial combination product consisting of the semisynthetic antibiotic piperacillin sodium and the beta-lactamase inhibitor tazobactam sodium for intravenous administration.
Piperacillin sodium is derived from D(-)aminobenzyl-penicillin. The chemical name of piperacillin sodium is sodium (2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazine-carboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1azabicyclo[3.2.0]heptane-2-carboxylate.
Tazobactam sodium, a derivative of the penicillin nucleus, is a penicillanic acid sulfone. Its chemical name is sodium (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide.
Piperacillin has an antimicrobial activity against a wide range of gm-ve organisms including K. pneumoniae, P. aeruginosa, Enterobacteriaceae and against gm+ve organisms eg E. faecalis and B. fragilis. Tazobactam is a penicillanic acid sulfone derivative with beta-lactamase inhibitory properties. In combination, tazobactam enhances the activity of piperacillin against beta-lactamase-producing bacteria.
Distribution Piperacillin and tazabactam: 30% bound to plasma proteins. Widely distributed into body tissues and fluids.
Metabolism Piperacillin: metabolised to a desethyl metabolite. Tazobactam: metabolised to a single metabolite that lacks pharmacological and antibacterial activities.
Excretion Half-life of piperacillin and tazobactam ranges from 0.7-1.2 hours. Eliminated via kidney by glomerular filtration and tubular secretion. Piperacillin: 68% excreted unchanged in urine.Tazobactam: 80% excreted unchanged in urine.
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Tazobactam inhibits many beta-lactamases, including staphylococcal penicillinase and Richmond and Sykes types II, III, IV, and V, including extended spectrum enzymes; it has only limited activity against class I beta-lactamases other than class Ic types.
Piperacillin and tazobactam may cause side effects such as upset stomach, vomiting, unpleasant or abnormal taste, diarrhea, gas , headache, constipation, insomnia, rash, itching skin, swelling, shortness of breath, unusual bruising or bleeding.
PIPTAZIN is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors.
Intravenous Injection vials should be stored at 20-25°C prior to reconstitution
